Endoaneurysmorrhaphy: Treatment Recommendations
Overview
Endoaneurysmorrhaphy is the procedure of choice for symptomatic left ventricular aneurysms, offering low perioperative mortality (5-5.7%), significant improvement in functional status, and excellent medium-term survival rates. 1, 2
This surgical technique involves opening the aneurysm sac and reconstructing the ventricular chamber from within, as opposed to simple exclusion or resection approaches.
Clinical Indications
Symptomatic Left Ventricular Aneurysms
- Endoaneurysmorrhaphy should be performed for all symptomatic ventricular aneurysms, particularly in patients with heart failure symptoms (NYHA class III or higher). 2
- The procedure results in significant amelioration of cardiac clinical status, with median NYHA class improving from III preoperatively to II postoperatively (p < 0.001). 2
Location Considerations
- Anterior-septal left ventricular aneurysms are the most common indication and carry lower surgical risk. 1
- Posterior left ventricular aneurysms can be treated with endoaneurysmorrhaphy but carry higher perioperative mortality (p=0.017), likely due to more severe baseline heart failure and larger ventricular volumes. 1
- Patients with posterior aneurysms present with higher LV end-diastolic volume index (138±38 vs. 102±41 ml/kg; p=0.040) compared to anterior-septal locations. 1
Surgical Outcomes and Prognosis
Short-Term Results
- Perioperative mortality ranges from 5.0% to 5.7%, which is acceptably low for this high-risk population. 1, 2
- Concomitant mitral valve surgery (p=0.008) and prolonged extracorporeal circulation time (p=0.001) are significant predictors of higher perioperative mortality. 1
Medium to Long-Term Outcomes
- Annual mortality during follow-up is 3.3% per year, with 5-year survival rate of 78%. 2
- Preexisting arterial occlusive disease and advanced age (>70 years) are significant predictors of medium-term mortality on multivariate analysis. 2
- Implantation of the left internal mammary artery during concomitant coronary revascularization is associated with better survival rates. 2
Critical Technical Considerations
Superiority Over Exclusion Techniques
- Endoaneurysmorrhaphy is recommended over simple ligation and exclusion when technically feasible. 3
- Excluded aneurysms without resection frequently expand over time: 32% increase in size (mean 5.9 mm), 20% remain unchanged, and only 48% decrease in size during follow-up. 3
- Contrast enhancement (analogous to type II endoleak) occurs in 44% of excluded aneurysm sacs, potentially leading to continued expansion and symptoms. 3
Surgical Approach
- Complete aneurysm excision or endoaneurysmorrhaphy should be performed rather than simple exclusion to prevent late complications including continued expansion and potential rupture. 3
- The technique involves opening the aneurysm sac, removing thrombus, and reconstructing the ventricular geometry from within using endocardial sutures. 2
Patient Selection Algorithm
Favorable Candidates
- Symptomatic patients with NYHA class II-IV heart failure 2
- Age <70 years (better medium-term survival) 2
- Absence of severe peripheral arterial occlusive disease 2
- Anterior-septal aneurysm location (lower surgical risk) 1
Higher Risk Patients (Requires Careful Individualized Assessment)
- Age >70 years (significant predictor of mortality) 2
- Posterior LV aneurysm location (higher perioperative mortality) 1
- Severe heart failure with markedly elevated LV end-diastolic volumes 1
- Need for concomitant mitral valve surgery (p=0.008 for mortality) 1
Important Caveats
- The presence of a posterior LV aneurysm is independently associated with higher perioperative mortality, though this may be confounded by more severe baseline heart failure in these patients. 1
- Concomitant coronary revascularization with internal mammary artery grafting should be performed when indicated, as it improves long-term survival. 2
- Simple exclusion without resection is inadequate and leads to continued aneurysm expansion in one-third of cases, similar to endotension after endovascular aortic repair. 3